Searchable abstracts of presentations at key conferences in endocrinology

ea0014p421 | (1) | ECE2007

Hypophosphatemic rickets and mutations in the PHEX gene

Faivre-Defrance Frédérique , Soudan Benoit , Marcelli-Tourvieille Sophie , Wémeau Jean-Louis , Vantyghem Marie-Christine

Hypophosphatemic rickets is associated with mutations in the PHEX gene leaving phosphaturic peptides such as FGF23 uncleaved, enabling them to exert their phosphaturic potential in the kidney. Other forms are caused by mutations in the proteolytic processing site of FGF23 itself, while in tumour-induced Hp, overproduction of FGF23 causes the processing capacity to be exceeded, resulting in phosphaturic Hp. The aim of this work was to assess blood FGF23 levels in Hp patients an...

ea0081p140 | Pituitary and Neuroendocrinology | ECE2022

Efficacy of lanreotide 120 mg primary therapy on tumor shrinkage and ophthalmologic symptoms in acromegaly after one month

Benderradji Hamza , Elise Vernotte , Ares Gustave Soto , Jean Philippe Woillez , Romain Perbet , Melodie-Anne Karnoub , Benoit Soudan , Arnaud Jannin , Assaker Richard , Luc Buee , Prevot Vincent , Claude-Alain Maurage , Pascal Pigny , Marie-Christine Vantyghem , Emilie Merlen , Cortet Rudelli Christine

Introduction: Few studies to date have attempted to evaluate the early efficacy of first-generation somatostatin analogs in somatotroph macroadenomas.Objective: To investigate the short-term efficacy of primary therapy with lanreotide 120 mg on tumor shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly.Design and patients: This single-center retrospective study included 21 patients who were newly diagno...